SHANGHAI, CHINA--(Marketwire - Sep 25, 2012) - Elsevier Business Intelligence and the BayHelix Group announced today that they awarded four prizes to celebrate innovation in China.
The 2012 BayHelix-Elsevier Awards were announced during an awards ceremony luncheon at the PharmAsia Summit Shanghai, September 25, 2012 at the Grand Hyatt Shanghai. Awards recipients were selected from a list of nominees submitted by members of the China and global pharmaceutical community. The award luncheon was hosted by Tony Zhang, PhD, VP, Global External R&D, Asia, Eli Lilly and Company, and former chairman of the BayHelix Group.
R&D Achievement of the Year recognizes a scientific discovery in China with direct impact to drug R&D or a significant achievement in pharmaceutical development milestones.
Professor Ningshao Xia and his team at Xiamen University were awarded for the development and imminent launch of the first Hepatitis E vaccine in the world.
Alliance of the Year recognizes a ground breaking pharmaceutical collaboration agreement involving a Chinese entity.
Hutchison MediPharma and AstraZeneca were awarded for completing a global licensing, co-development, and commercialization agreement for Volitinib, a novel, targeted therapy entering Phase I clinical trial for the treatment of cancer. This partnership represents the first time a major pharmaceutical company has directly licensed a novel clinical ready stage molecule from a biotech company in China, with plans to develop and commercialize it globally, with record setting initial cash payment of US$20 million and further milestone payments of $120M.
Commercial Achievement of the Year recognizes a creative model that delivered superior value to patients/payers in China and commercial success.
ZheJiang BetaPharma was awarded for the successful launch of cancer drug Commana™ (icotinib) and its innovative model of providing free access to the drug after certain period of staying on the therapy.
R&D Leadership Award recognizes an outstanding individual whose contributions have changed the landscape, reputation, and ecosystem for drug R&D in China.
Steve Yang, VP, Head of R&D for Asia & Emerging Markets, AstraZeneca PLC., was awarded for his service, wisdom and influence among international pharmaceutical R&D communities.
The PharmAsia Summit, sponsored by Elsevier Business Intelligence and the BayHelix Group, was held September 24-26 in Shanghai. The Summit featured research reports, presentations, and case studies from China, India and other emerging markets focusing on two key imperatives of innovation: (1) Getting Better Products To Market Faster; and (2) Creating Value For Patients And Payers.
For further information, please visit: http://www.PharmAsiaSummit.com.
Elsevier Business Intelligence, a global leader in the field of healthcare industry information, provides business intelligence on regulatory, business and reimbursement issues that are vital to the healthcare industry. Through a range of products including publications, conferences, e-learning, databases and reports, Elsevier Business Intelligence places biopharma and medical device professionals, and those who focus on these industries, at the forefront of knowledge, by providing the perfect combination of news and information together with penetrating insight and analysis. Our leading publications include PharmAsia News, IN VIVO and "The Pink Sheet." For more information, visit: http://www.ElsevierBi.com.
About BayHelix Group:
BayHelix is an organization of leaders of Chinese heritage in the global life sciences and healthcare community. We aspire to shape the growth of the life sciences and healthcare industry around the Pacific Rim and beyond, foster and create business opportunities, supply and nurture the leaders for the community, and network and share information and experience. BayHelix is a non-profit organization and its membership is by-invitation-only. For more information, visit: http://www.bayhelix.org.